Case | Authors | Age | Pathological features | NAC regimens |
---|---|---|---|---|
1 | Chen et al. [3] | 48 | ER(−), PR(−), HER2(−)Ki-67(60%) | TC 4 cycles |
2 | Alan et al. [4] | 72 | ER(≤ 1%), PR(−), HER2(−), Ki-67 (N/A) | wPTX + EC |
3 | Noro et al. [5] | 40 | ER(−), PR(−), HER2(−)Ki-67(N/A) | AC 1cycle + wPTX 12cycles |
4 | Usui et al. [6] | 48 | ER(−), PR(−), HER2(+)Ki-67(N/A) | Dose-dense AC 4cycles, HP + DTX 4cycles |
5 | Sakuma et al. [7] | 57 | ER(−), PR(−), HER2(−)Ki-67(N/A) | EC 4cycles DTX 4cycles |
6 | Dejager et al. [8] | 61 | ER(−), PR(−), HER2(+)Ki-67(N/A) | CDDP + 5-FU |
7 | Present case | 56 | ER(−), PR(−), HER2(−)Ki-67(90%) | Dose-dense AC 4cycles, Dose-dense PTX 4cycles |